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Summary Antineoplastic compounds can induce on tumour cells new antigens that indetectable on parental
cells and which are transmissible as a genetic character. In this study mouse leukaemia L1210 was cloned in
vitro by limiting dilution and one cloned line was recloned in vivo. Four subcloned tumour cell lines
(A,D, R, S) were xenogenized in vivo by DTIC treatment (A/DTIC,D/DTIC, R/DTIC,S/DTIC) following a
schedule previously described. Up to 107 cells of these xenogenized subclones, injected i.p., were rejected by
syngeneic hosts, although they grew in immunosuppressed hosts.
The DTIC treated subclones were lysed by in vivo-primed, in vitro-restimulated (with the relevant subclone)
lymphocytes.
The cytotoxic lymphocyte activity was not strictly specific since parental, DTIC-untreated cells were also
lysed, although less efficiently.
CTL directed against the D/DTIC subclone were cloned by limiting dilution. Ninety-four CTL clones were
assayed against L1210 subcloned cells, DTIC-treated and untreated, and against different murine tumours
(syngeneic or allogenic). Three specific antigens could be identified in the 'tCr release assay. The DTIC
subclones expressed one antigen that was specifically recognized by a set of CTL clones. A number of CTL
clones were able to lyse the L1210 subcloned cell exclusively, targetting a tumour-associated antigen that did
not appear to be modified in the DTIC-treated subclones. A third antigen was demonstrated in the parental
and DTIC treated D subclone.
On the basis of these results it was postulated that there was at least one common DTIC-inducible antigen
specific and reproducible within an identical cell population. Moreover, DTIC treatment did not modify
histocompatibility antigens or TAA pre-existing in L1210 cells.
The findings discussed here provide new information about permanent xenogenization of tumour cells,
which might be exploited for experimental chemo-immunotherapy of cancer.
In recent years, attempts to xenogenize tumour cells have
been pursued in a number of laboratories. It has been
achieved by several procedures, including exposure to non-
pathogenic viruses (Lindenman et al., 1963; Kobayashi et al.,
1970), antitumour drugs (Bonmassar et al., 1970; Nicolin et
al., 1972), through chemical haptenization (Martin et al.,
1971) or treatment with mutagens (Boon & Kellerman,
1977).
The antitumour agent, (5-(3,3' dimethyl-l-triazeno)-
imidazole-4-carboxamide (DTIC), employed in our experi-
ments, has been found to be particularly effective in increas-
ing the immunogenicity of certain experimental lymphomas
(Bonmassar et al., 1972; Nicolin et al., 1976a).
The new antigenic specificities, not detectable on parental
cells are retained as a genetic character after cessation of
DTIC treatment (Nicolin et al., 1974a) and induce an
immune response in syngeneic hosts as evaluated by classical
rejection experiments (Nicolin et al., 1976b; Riccardi et al.,
1978) and by transfer of immune lymphocytes (Nicolin et al.,
1974b; Nicolin et al., 1980; Romani et al., 1983).
Furthermore, it has been shown that DTIC-altered tumour
cells can elicit host resistance to a subsequent inoculum of
untreated tumour cells (Campanile et al., 1975; Nicolin et al.,
1981). In this respect DTIC treatment of tumour cells is
likely to have some significance for immunotherapeutic
approaches against neoplastic cells.
However, many fundamental questions related to the
mechanism of immunological alterations and to the molecu-
lar characteristics and the functions, if any, of the DTIC-
induced antigens remain unanswered.
The aim of this study was to further investigate antigenic
changes detected in the tumour cell surfaces after DTIC
treatment. We wished to know whether DTIC induces new
antigen(s) (Bonmassar et al., 1979) rather than amplifying a
pre-existent tumour-associated antigen (TAA) (Mihich, 1969;
Fuji et al., 1979) or induces a product that behaves like a
restriction element for the recognition of an antigen already
expressed on untreated tumours (Hui et al., 1984). Another
purpose of this study was to determine the immunological
relationship among genetically homogeneous L1210 cells,
distinctly xenogenized through different cycles of DTIC
treatments, using syngeneic cytolytic T-lymphocytes (CTL)
and the derived clones.
Materials and methods
Animals
Hybrid (BALB/c H-2d xDBA/2 H-2d)F1 (hereafter called
CD2F1) mice of both sexes, 6-8 weeks old were obtained
from Charles River Breeding Laboratories (Calco, Italy).
Tumours
L1210 Cr (H-2d) (Law et al., 1949; Dunham et al., 1953)
obtained from the National Cancer Institute (Bethesda,
USA) and maintained in the laboratory by weekly i.p.
injection into CD2F1 mice was cloned in vitro by limiting
dilution. Twenty cells from one clone (20 cells/4ml) were
injected (0.2ml/mouse) into 20 syngeneic mice. Four of 8
subcloned tumour lines (referred to as A, D, R, S) were
transformed in vivo with DTIC, as previously described
(Bonmassar et al., 1970). Briefly, 106 tumour cells were
injected i.p. into CD2F1 mice treated for 7 consecutive days
with DTIC (100mgkg -1day-1, i.p.) starting one day after
tumour challenge. When the ascitic tumours developed in the
DTIC-treated mice, they were collected and 106 cells were
transplanted into untreated mice. The same procedure was
followed for 4-5 transplant generations.
Immunogenic subclones A/DTIC, D/DTIC, R/DTIC, S/
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DTIC were maintained in compatible, total body X-
iiradiated (3.5Gy; Securix Compact CGD), mice.
-YAC-1(H-2a) tissue culture cell line originating from
YAC (Klein & Klein, 1964) was maintained in RPMI 1640
medium (Flow Lab.) supplemented with 10% heat-
inactivated foetal calf serum (FCS) (Flow Lab.),
100Um-1 penicillin, 100pgml- streptomycin.
P388 (H -2d) tumour cells (Dawe & Potter, 1957) were
maintained by weekly i.p. injections into syngeneic DBA/2
mice.
Preparation of T-cell growth factor (TCGF) from rat spleen
cells
Rat spleen cells (5-10 x 106 cellsml -1) were cultured for 24h
in RPMI 1640 medium supplemented with 10% heat inacti-
vated FCS, 5 x 10-5M 2-mercaptoethanol, 100 pml- peni-
cillin, 100pgml-l streptomycin and 2-5ypgml-
Concanavalin A (Flow Lab.).
The supernatant that contained TCGF was collected by
centrifugation, filtered and stored at -20°C.
Cytotoxic T lymphocytes (CTL) and 51Cr release assay
Spleen cells from CD2F1 mice injected 3-5 weeks before
with 107 DTIC treated subclones were stimulated secondarily
in vitro.
30 x 106 splenocytes (responders) were cultured in 25cm2
flasks (Sterilin) with 3 x 106 mitomycin C (Kiowa, Tokyo)-
treated tumour cells (stimulators) at a final volume of 20ml
RPMI 1640 medium, supplemented as previously described.
After 5 days incubation, the effector CTL were harvested
and their lytic activity against different target cells was
evaluated in a "Cr release microassay (Ferrini et al., 1987).
Briefly, 5'Cr-labelled target cells, 104 in 100 p1, were
seeded in 96 well plates (Sterilin) with lOOpul effector cells at
different concentrations and incubated for 4h at 37°C in a
moist atmosphere of 95% air and 5% CO2. The plates were
then centrifuged and 100p1 supernatant counted in a gamma
counter. Percent specific lysis was calculated as:
% lysis cpmexp. release -cpmspontaneousrelease 100
cpm max. release- cpm spontaneous release
Maximum release was obtained by incubating 104 5"Cr
labelled target cells in 200/p1 Triton-X100 (1% in distilled
water) for 4h. Spontaneous release was obtained by incubat-
ing 104 target cells with different concentrations of non-
secondarily activated syngeneic splenocytes. The spontaneous
51Cr release for the target cells used was in the range,
5-15%.
CTL cloning
Ten CTL, obtained as previously described, were placed in
flat-bottom 96 well plates (Linbro Chemical Co.) under
limiting dilution conditions (1, 10 and 100 cells per well)
with 5 x104 previously irradiated (60Gy; 60Co) stimulator
cells, 104 irradiated (40Gy; 60Co) syngeneic cells per well as
feeders, and 10% TCGF.
The three plates seeded with 1 cell/well did not develop a
colony, the 3 plates seeded with 10 cells/well developed a
colony in 33% of the wells and when 100 cells were seeded
colonies grew in almost all the wells. CTL clones used in this
work derive from the plates seeded with 10 cells/well.
Virus detection
Cell culture supernatants were filtered (0.2 pm FlowPore D)
and assayed for ecotropic murine retroviruses in mouse SC-1
cells by the XC plaque assay (Varnier & Levy, 1979; Rowe
et al., 1970).
No infectious virus (<4 Plaque Forming Unitml-1) was
detected in the samples.
The electron microscopic localization of MMTV antigens
was performed by the pre-embedding protein A-gold
technique.
Results
Cloned cells from the mouse L1210 leukaemia, obtained by
'limiting dilution' in vitro, were inoculated (20 cells in 4ml),
i.p. into 20 syngeneic CD2F1 mice (0.2nml/mouse). Four of
the 8 tumour subclones (A,D,R,S) that grew in the mice,
were xenogenized in vivo by DTIC treatment, as previously
described (Bonmassar et al., 1970). Following 4-5 transplant
generations the A/DTIC, D/DTIC, R/DTIC, S/DTIC sub-
lines were fully xenogenized, since 107 cells of each subclone
were completely rejected by CD2F1 mice. The experimental
results in Table I show that xenogenized DTIC subclones
retained the growth characteristics of the untreated L1210
parental subclones, since their tumorigenicity in immunosup-
pressed mice was fully retained.
The antigenic properties of the L1210/DTIC subclones and
their reciprocal immunological relationships were studied
with CTL. Spleen cells from CD2F1 mice that had rejected
107 xenogenized cells were secondarily restimulated in vitro
with the relevant DTIC subclones. The results for the
immunological cross-reactivities among L1210 DTIC sub-
clones are listed in Table II.
In the 4h 51Cr-release assay, anti-D/DTIC CTL had high
lytic activity against D/DTIC target cells as well as against
the other DTIC subclone lines. The parental, DTIC-
untreated D subclone line was also lysed by anti-D/DTIC
CTL, although the percentage of 51Cr release was lower than
that released by D/DTIC. The other untreated cell lines
(A,R,S) were recognized and lysed to a lesser degree than
D. There was detectable activity against YAC and P388
lymphomas. Similar patterns of cross-reactivity were dis-
played by anti-A/DTIC, anti-R/DTIC and anti-S/DTIC CTL
(data not shown). Indeed the CTL to each xenogenized
subclone were fully cross-reactive with the other DTIC
treated subclones.
To further understand the antigenic properties of DTIC
subclones, D/DTIC CTL were cloned in microtiter plates by
limiting dilution and cultured in the presence of irradiated
D/DTIC cells, syngeneic feeder spleen cells and rat IL-2.
Three weeks later, it was possible to detect growing colonies
in 94/288 microwells. Since the percentage of negative wells
was -67%, a high probability of cloning was ensured. The
cytotoxic activity (lytic activity) of individual clones was
assayed against the xenogenized cells, the untreated parental
subclones and unrelated tumours. Twenty-one of the 94 CTL
clones obtained had no lytic activity and 73 had cytotoxic
activity. Among the 73 effective CTL clones, 36 had high
cytotoxic activity against the 4 xenogenized subclone cells
only (Table III), in contrast to the 12 CTL clones that had
lytic activity against the L1210 subclone cells also (Table
IV), whether xenogenized or not. None of the CTL clone
groups had any effect on the unrelated tumour cells. Two
CTL clones were weakly but highly specifically lytic to the
Table I Growth patterns of L1210 subclones in normal
and immunosuppressed mice
Intact mice Irradiated mice
Tumour cells? MSTb D/TC MST D/T
D 6.5 10/10 6 10/10
D/DTIC - 0/10 6.5 10/10
A 7 10/10 6.5 10/10
A/DTIC - 0/10 7 l1/l0
R 6.5 10/10 6 10/10
R/DTIC - 0/10 7 10/10
S 7 10/10 7 10/10
S/DTIC - 0/10 7.5 10/10
a107 viable cells/mouse, i.p.; bMST=mean survival time;
cD/T=dead mice/treated mice; d3.5Gy/mouse (day-1).CTL AGAINST DTIC INDUCED ANTIGEN 173
Table II Anti-D/DTIC CTL activity: percentage 5'Cr release (±s.d.)
Target
cells 20: a 10:1 5:1 2.5:1 1:1
D/DTIC 94.4+7.8 81.4+7.2 71.4+5.2 56.9+4.2 35.9+2.1
D 51.9+4.3 31.9+1.8 17.1+9.9 11.1+0.3 2.5+0.1
A/DTIC 43.9+3.1 34.6+1.9 28.5+1.1 23.7+1.2 17.2+0.7
A 15.0+ 1.2 9.6+0.5 7.7+0.4 2.7+0.1 0.2+0
R/DTIC 79.3+6.1 66.2+4 58.9+4.1 52.4+3.9 25.9+1.5
R 39.9+2.9 26.2+1.1 21.8+1.2 12.9+0.9 5.5+0.4
S/DTIC 84.3+7 73.4+5.1 64.4+4.2 48.9+3.1 25.9+1.9
S 24.9+1.9 19.0+0.1 17.0+1.2 5.6+0.3 2.1+0.1
YAC 14.2+0.9 9.9+0.5 2.6+0.1 1.6+0.2 0.4+0
P388 19.4+1.2 9.6+0.8 9.2+0.4 6 +0.4 3.4+0.2
aEffector: target cell ratio.
Table m Anti-D/DTIC CTL clones: Specific lysis of DTIC subclones
Clone no.
Target
cells 11 14 33 69 85
D 3.2+0.2a 0.6+0 0.8+0.1 8.1 +0.7 7.0+0.3
D/DTIC 83.9+6.2 78.9+6.9 62.5+3.9 87.3+7.1 82.9+7.2
A 2.1+0.1 0.5+0 3.2+0.5 8.2+0.9 2.3+0.4
A/DTIC 81.4+7 84.4+7.1 71.4+4 79.4+6.2 78.7+5.9
R 7.3+0.7 3.5+0.4 6.9+0.6 0.3+0 2.1+0.1
R/DTIC 77.9+6.4 79.5+5.2 84.1+6.2 69.5+5.9 71.9+6
S 5.3+0.4 5.3+0.5 0.2+0 3.2+0.3 6.4+0.6
S/DTIC 80.5+7.1 80.2+7 72.7+4.9 68.9+5.6 79.8+6.1
YAC 4.2+0.3 2.1+0.3 11.2+0.7 0.6+0 6.5+0.5
P388 7.7+0.6 3.4+0.2 0.2+0 9.3+0.8 8.2+0.6
EL4 1.1+0 1.2+0 10.3+0.7 7.2+0.5 3.4+0.1
Similar activities were displayed by 31 CTL clones not reported here; 1% 51Cr
release+s.d.; Effector:target cell 5: 1.
Table IV Anti-D/DTIC CTL clones: Lysis of L1210 subclones
Clone no.
Target
cells 6 16 48 52 78
D 68.5+3.la 62.6+4.5 73.5+6.2 57.2+3.9 81.9+7
D/DTIC 71.8+4 66.7+3.2 68.4+4.7 80.4+7 58.2+3.2
A 73.6+3.9 78.2+5.1 58.0+3.2 56.3+4 76.6+5.2
A/DTIC 64.7+2.2 68.9+4 76.6+5.2 59.2+3.9 69.4+5
R 59.6+2.8 78.7+5.4 74.4+6.4 66.5+4.1 74.9+5.9
R/DTIC 77.2+4.6 73.9+4.2 56.3+4.2 72.9+4.3 62.1+4.2
S 61.5+3.4 68.5+3.9 77.2+5.9 62.9+3.9 81.1+6.9
S/DTIC 65.6+4.2 70.6+ 5.2 74.9+6 63.7+3.8 63.2+4.3
YAC 4.3+0.1 8.3+0.6 2.3+0.1 5.4+0.6 0.4+0
P388 3.2+0.2 0.2+0 8.4+0.4 7.2+0.7 6.3+0.6
EL4 1.3+0 8.9+0.5 2.9+0.2 4.3+0.2 3.2+0.1
Similar activities were displayed by 7 CTL clones not reported here; 8% 5 Cr
release+s.d.; Effector:target cell 5:1
Table V Anti-D/DTIC CTL clones:
Specific lysis (% +s.d.) of D subclones
Clone no.
Target cells 32 57
D 28.3+1.5a 34.3+1.6








P388 7.1 +0.9 2.6+0.4
EL4 4.0+0.1 1.7+0.5
a% 51Cr release; Effector:Target cell 5:1.




Target cells I II III
D/DTIC +++ +++ +
D - +++ +
A/DTIC + + + + ++ -
A _ ++
R/DTIC + + + + ++ -
R - +++ -
S/DTIC +++ +++ -
S - +++ -
YAC - - -
P388 - - -
EL4 - - -
Note: + + + 60-80% specific 51Cr release;
+ 30% specific 51Cr release.174 0. MARELLI et al.
D/DTIC subclone and its corresponding D parental subclone
(Table V). The specific activity of CTL clones could there-
fore be differentiated into three groups, (Table VI). The last
23 CTL clones had no specific activities, since they showed
different patterns of reactivity. All of them were able to lyse
the L1210 derived lines, YAC cells and different non-related
tumour cell lines (P388, L5178Y, EL4), but the degree of
lysis of each target cell was different, clone by clone (data
not shown). The pattern of activity of these clones is the
pattern of reactivity described for activated NK (Henney et
al., 1981; Suzuki et al., 1983) and/or LAK cells (Rosenstein
et al., 1984; Merluzzi, 1984).
Discussion
This laboratory has been involved in attempts to elucidate
the immunological alterations in L1210 leukaemia after
treatment with the anticancer agent DTIC. Briefly, DTIC-
treated L1210 cells are rejected by immunocompetent synge-
neic animals, even after very heavy cell challenges in spite of
the fact that these cells show the same kinetic properties as
those ofparental L1210 cells both in vitro and in immunode-
ficient hosts (Silvestrini et al., 1977). The modification at the
molecular level is still unknown. Studies of DTIC-induced
antigenicity and of similar immunological alterations pro-
duced in different tumour cells by other anticancer com-
pounds (Mihich, 1969; Nicolin et al., 1972; Frost, 1984), or
mutagenic agents (Boon, 1983; Altevog et al., 1985), have
been hampered by difficulties in raising effective polyclonal
or monoclonal antibodies. Further characterization of DTIC
antigens might be useful in shortening the time schedule
required to xenogenize the tumour cells, in order to achieve
the tumour rejection in primary hosts. Furthermore the
DTIC-induced antigens might be exploited for active vacci-
nation or passive immunotherapy.
Previous studies with cell-mediated cytotoxic assays from
this laboratory (Marelli et al., 1986) have excluded the
likelihood that DTIC positively selects naturally occurring
non-tumorigenic cells and indicate that there is a limited
number of antigens in DTIC-treated L1210 cells. The
number ofantigens expressed by DTIC-treated L1210 cells is
still not exactly defined because of the genetic heterogeneity
of the tumour populations.
In this study, we found that four L1210 subclones,
submitted separately to DTIC treatments, were not tumori-
genic in syngeneic hosts although they were as tumorigenic
as untreated subclones in immunodepressed mice. The gene-
tic homogeneity within the four subclones, rendered it
impossible for DTIC to select preexisting non-tumorigenic
variant cells from the L1210 subclones. Therefore, we
assume that the antigenic properties of treated L1210 sub-
clones were directly altered by DTIC treatment.
Serological studies carried out in collaboration with the
Tissue Typing Research Laboratories of the London Hospi-
tal Medical College (Marelli & Kimura, unpublished obser-
vations) provide no evidence for qualitative and/or
quantitative differences of MHC class I antigen expression in
the parental and DTIC treated cells. All the subclones
(DTIC treated and untreated), as well as the L1210 line from
which they were derived, were negative for MHC class II
antigen expression.
It was therefore of interest to establish the number of
antigens expressed on each DTIC subclone as well as to
study the immunological relationships among the subclones.
Since all four CTL populations lysed all four DTIC sub-
clones, the immunological cross-reactivity of the DTIC sub-
clones was proven. However, parental subclones and NK
sensitive YAC cells were also lysed although less efficiently. Therefore, we have not established the number of DTIC
antigenic specificities on the cells, not whether the DTIC
subclones expressed new antigens or overexpressed the L1210
TAA putatively responsible for the partial CTL cross reacti-
vity. Moreover the possibility that the increased antigenicity
was due to the induction of a product that behaves like a
restriction element for the recognition of an antigen already
expressed on untreated tumour cells, could not be ruled out.
These questions were approached by testing the CTL clones
obtained from the anti-D/DTIC CTL population against the
battery of relevant target cells. As shown in Table VI, three
types of specific antigens could be identified. A number of
CTL clones were able to effectively lyse only the DTIC
subclones.
These results concur with the hypothesis that a new
antigen (or set of antigens) is induced by DTIC treatment.
To date, every property related to the drug treatment and
expressed on D/DTIC cells is shared by all the other DTIC-
modified lines. However, the design of our studies does not
exclude in principle that within A/DTIC, R/DTIC or S/
DTIC cell populations there might be other products not
shared with the D/DTIC cell population. Likewise, within D/
DTIC there might be cells carrying determinants unrecog-
nized by the CTL clones studied here and unique for D/
DTIC lines. Investigations relating to virus infection have
excluded differences among parental and DTIC subclones.
All L1210 tumour lines and P388 used here were positive for
mammary tumour virus (Squartini & Marchetti, unpublished
data), as determined in an immunocytochemical study with
rabbit anti-MTV serum and protein A-gold complexes, while
they were negative for type C viruses (Varnier, unpublished
data) in plaque assays. On the basis of these observations we
can postulate the existence of a reproducible and specific
DTIC-induced antigen responsible for genetic and phenoty-
pic xenogenization of L1210 leukaemia.
The biochemical structure of the DTIC induced antigen is
unknown. This study shows that the TAA of L1210 is not
functionally modified, since a set of cytotoxic cloned CTL
did not discriminate between parental and DTIC-treated
cells. This antigen(s) cannot be responsible for host rejection,
since challenge with as few as 10 cells of parental subclones
was lethal. Although it is quite likely that this common
determinant is comparable with a TAA expressed on L1210,
since P388 and YAC cells are not recognized, we cannot rule
out the possibility that these cross-reactivities might be due
to the presence of viral products (Racevskis & Sarkar, 1982;
Zac-Nejmark et al., 1978).
Two CTL clones showed weak but highly specific reacti-
vity against the immunizing target (D/DTIC) cells and the
respective untreated lines (D). Although the parental cell
lines D, A, R, S were derived from one clone of L1210, a
mutational event occurred before the DTIC treatment could
be responsible for the induction of a determinant on the
untreated D cell line that is retained on D/DTIC cells. The
antigens recognized by the 23 clones that behave in a
nonspecific way could belong to the category of molecules
that are targets for LAK or activated NK.
We did exclude that they are classical NK targets, since
L1210 cells (Fuji & Iribe, 1986) were not NK sensitive.
Moreover the parental and DTIC treated subclones involved
in this study were not lysed in classical NK experiments
(data not shown).
Little is known so far about the mechanism by which
alkylating compounds, such as DTIC (Audette et al., 1973),
have such a strong effect on the immunogenicity of tumour
cells. Since DTIC treatment has to be protracted to obtain
tumour lines rejected by a syngeneic host, it is quite likely
that more than one mutational event occurs, but probably
only a few of these lead to increased antigenicity. Further-
more, our results suggest that DTIC induces mutations,
leading to the recurrent expression of new antigens at
preferential sites.
Studies are in progress to elucidate the biochemistry and
genetics of DTIC induced-antigens.
Whatever the chemical structure of the DTIC-induced
antigens, the data presented in this paper may prove useful
for a chemo-immunological approach to tumour therapy.
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